Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Asako Nagata"'
Autor:
Brion W. Murray, Todd VanArsdale, Asako Nagata, Xiu Yu, You-Ai He, Wade Diehl, James Solowiej, Simon Bergqvist, Hieu Lam, Rose Ann Ferre, Meirong Xu, Wenyue Hu, Nathan V. Lee, Ping Chen
Table S1. Statistics for the crystallographic analysis; Table S2. Biochemical and cellular potencies of the second generation CDK-directed drug AG-024322; Table S3. In vitro analysis of binding potency of abemaciclib, dinaciclib, and palbociclib to n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8204016bf848a963e3585eed80370df5
https://doi.org/10.1158/1535-7163.22503270
https://doi.org/10.1158/1535-7163.22503270
Supplemental Methods from Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Autor:
Brion W. Murray, Todd VanArsdale, Asako Nagata, Xiu Yu, You-Ai He, Wade Diehl, James Solowiej, Simon Bergqvist, Hieu Lam, Rose Ann Ferre, Meirong Xu, Wenyue Hu, Nathan V. Lee, Ping Chen
Detailed description of the methods used in the manuscript
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8030e81408c3dad60f8f11d969017a28
https://doi.org/10.1158/1535-7163.22503273.v1
https://doi.org/10.1158/1535-7163.22503273.v1
Autor:
Luping Qiu, Kymberly Levine, Ketan S Gajiwala, Ciarán N Cronin, Asako Nagata, Eric Johnson, Michelle Kraus, John Tatlock, Robert Kania, Timothy Foley, Shaoxian Sun
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198374 (2018)
Protein tyrosine kinase 6 (PTK6, or BRK) is aberrantly expressed in breast cancers, and emerging as an oncogene that promotes tumor cell proliferation, migration and evasion. Both kinase-dependent and -independent functions of PTK6 in driving tumor g
Externí odkaz:
https://doaj.org/article/14826eba87d1454caa8322f0b783ae9f
Autor:
Kephart Susan Elizabeth, Tran Khanh Tuan, Kevin Daniel Freeman-Cook, Sherry Niessen, James Solowiej, Buwen Huang, Qin Zhang, Douglas Carl Behenna, Inish O'Doherty, Sacha Ninkovic, Rose Ann Ferre, Andrea Hui, Nichol Miller, Jordan Carelli, Lisa Nguyen, Brion W. Murray, Robert Louis Hoffman, John Lapek, Rhys M. Jones, Meirong Xu, Stephen Dann, Sutton Scott Channing, Asako Nagata, Nanni Huser, Ravi Visswanathan, Zehnder Luke Raymond, Elaine E. Tseng, Britton Boras, You-Ai He, Michele McTigue, Wade Diehl, Cathy Zhang, Martha A. Ornelas
Publikováno v:
Journal of medicinal chemistry. 64(13)
Control of the cell cycle through selective pharmacological inhibition of CDK4/6 has proven beneficial in the treatment of breast cancer. Extending this level of control to additional cell cycle CDK isoforms represents an opportunity to expand to add
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8850d384322d3198a875fe9a0d1ad8ea
https://pubmed.ncbi.nlm.nih.gov/34110834
https://pubmed.ncbi.nlm.nih.gov/34110834
Autor:
Xinmeng Jasmine Mu, Meirong Xu, Shahram Salek-Ardakani, Cinthia Costa-Jones, Lisa Nguyen, James Solowiej, David Looper, Scott L. Weinrich, Robert Louis Hoffman, Sutton Scott Channing, Sacha Ninkovic, Kephart Susan Elizabeth, Sherry Niessen, John Chionis, Jadwiga Bienkowska, Kevin Daniel Freeman-Cook, Rose Ann Ferre, John Lapek, Cecilia Oderup, Jordan Carelli, Cathy Zhang, Nanni Huser, Elizabeth A. McMillan, Asako Nagata, Martha A. Ornelas, Brion W. Murray, Douglas Carl Behenna, Koleen Eisele, Todd VanArsdale, Zhou Zhu, Zhengyan Kan, Chaoting Liu, Nichol Miller, Zehnder Luke Raymond, Michael A. White, Ying Ding, Nathan V. Lee, Jonathan Almaden, Qin Zhang, Tran Khanh Tuan, Ping Wei, Stephen Dann, Britton Boras, Tim S. Wang, Ravi Visswanathan, You-Ai He, Michele McTigue, Elizabeth Wilson
Publikováno v:
Cancer Cell. 39:1404-1421.e11
Summary The CDK4/6 inhibitor, palbociclib (PAL), significantly improves progression-free survival in HR+/HER2− breast cancer when combined with anti-hormonals. We sought to discover PAL resistance mechanisms in preclinical models and through analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed89e2bd873344dd19ed1d4ed19277ab
https://doi.org/10.1016/j.ccell.2021.08.009
https://doi.org/10.1016/j.ccell.2021.08.009
Autor:
Chengyi Zhang, Sujin Cho-Schultz, Tran Khanh Tuan, Manli Shi, Rose Ann Ferre, Sherry Niessen, Sajiv Krishnan Nair, Douglas Carl Behenna, Dac M. Dinh, Elaine E. Tseng, Theodore O. Johnson, Cheng Hengmiao, Ru Zhou, Michael Zientek, T. Eric Ballard, Brion W. Murray, Suvi T. M. Orr, James Solowiej, Jennifer Lafontaine, Jean Joo Matthews, Scott L. Weinrich, Paolo Vicini, Deal Judith G, Longqing Liu, John Charles Kath, Pairish Mason Alan, Simon Paul Planken, Louise Bernier, Deepak Dalvie, Yiqin Luo, Martin Paul Edwards, Asako Nagata, Hong Shen, Neal W. Sach, Yuli Wang, Ketan S. Gajiwala, Shuibo Xin, Simon Bailey, Chau Almaden, Robert Steven Kania, Michelle Hemkens
Publikováno v:
Journal of Medicinal Chemistry. 60:3002-3019
Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b35c90cb7e71bbfee825479df1f470d5
https://doi.org/10.1021/acs.jmedchem.6b01894
https://doi.org/10.1021/acs.jmedchem.6b01894
Autor:
Marlena Walls, Tod Smeal, Suvi T. M. Orr, Zhengyu Liu, Cheng Hengmiao, Shuiwang Wang, Kephart Susan Elizabeth, Jean Joo Matthews, Rose Ann Ferre, Neal W. Sach, Scott L. Weinrich, Doug Behenna, Sherry Niessen, Sangita M. Baxi, Deepak Dalvie, Sujin Cho-Schultz, Dac M. Dinh, Kevin Ryan, Jim Solowiej, Elaine E. Tseng, Simon Paul Planken, Sajiv Krishnan Nair, Brion W. Murray, Jun Li Feng, Jennifer Lafontaine, Pairish Mason Alan, Shijian Ren, Michelle Hemkens, Shuibo Xin, Mehran Jalaie, Tran Khanh Tuan, Robert Steven Kania, Sutton Scott Channing, William F. Vernier, Kevin K.-C. Liu, Amy Jackson-Fisher, Beth Lunney, Min-Jean Yin, Ketan S. Gajiwala, Asako Nagata, Haiwei Xu, Michael Zientek, Ru Zhou, Daniel Tyler Richter, Simon Bailey, Martin Paul Edwards, Martha A. Ornelas, Chau Almaden, John Charles Kath, Hong Shen, Theodore O. Johnson
Publikováno v:
Journal of Medicinal Chemistry. 59:2005-2024
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease progresses, often driven by a second-site mutation in the EGFR kinas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcd650965ee5ecc3e2b378a7f2542e1b
https://doi.org/10.1021/acs.jmedchem.5b01633
https://doi.org/10.1021/acs.jmedchem.5b01633
Autor:
Michelle Tran-Dubé, Bruce M. Bechle, Michelle Kraus, Ciarán N. Cronin, Kim James, Joseph S. Warmus, Fen Wang, Jianmin Sun, Indrawan James Mcalpine, Sacha Ninkovic, Jianwei Bian, Samantha Elizabeth Greasley, Neil J. Flanagan, Matthew Corbett, Rebecca Dias, Andrews Mark David, Asako Nagata, John F. Braganza, Linda Kitching, David C. Blakemore, Eric Johnson, Sarah Elizabeth Skerratt, Kiyoyuki Omoto, Sharan K. Bagal, Jingrong Jean Cui, James Bilsland, Peter J. Bungay, Rachel L. Grimley, Stephanie Scales, Gareth Waldron
Publikováno v:
Journal of medicinal chemistry. 61(15)
Hormones of the neurotrophin family, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4), are known to activate the family of Tropomyosin receptor kinases (TrkA, TrkB, and TrkC). Moreove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f470c72f1e1c68f507f99de2c39e1f77
https://pubmed.ncbi.nlm.nih.gov/29944371
https://pubmed.ncbi.nlm.nih.gov/29944371
Autor:
Robert Steven Kania, Eric Johnson, Tatlock John H, Luping Qiu, Timothy L. Foley, Shaoxian Sun, Kymberly Levine, Ketan S. Gajiwala, Ciarán N. Cronin, Michelle Kraus, Asako Nagata
Publikováno v:
PLoS ONE
PLoS ONE, Vol 13, Iss 6, p e0198374 (2018)
PLoS ONE, Vol 13, Iss 6, p e0198374 (2018)
Protein tyrosine kinase 6 (PTK6, or BRK) is aberrantly expressed in breast cancers, and emerging as an oncogene that promotes tumor cell proliferation, migration and evasion. Both kinase-dependent and -independent functions of PTK6 in driving tumor g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed360b0109ea048c220a42f22b9203e
http://europepmc.org/articles/PMC5991704
http://europepmc.org/articles/PMC5991704
Autor:
Michelle Kraus, James Bilsland, Neil J. Flanagan, Gareth Waldron, Linda Kitching, Indrawan James Mcalpine, Peter J. Bungay, Jingrong Jean Cui, David Fengas, Rachel L. Grimley, Joseph S. Warmus, Ciarán N. Cronin, Samantha Elizabeth Greasley, Philip J Clarke, David C. Blakemore, Asako Nagata, Eric Johnson, Sharan K. Bagal, Rebecca Dias, Kiyoyuki Omoto, Matthew Corbett
Publikováno v:
Journal of medicinal chemistry. 62(1)
Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are activated by hormones of the neurotrophin family: nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4 (NT4). Moreover, the NGF antibody tane
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::783bc10c50e46e9fccee1aeb733dbfb1
https://pubmed.ncbi.nlm.nih.gov/29672039
https://pubmed.ncbi.nlm.nih.gov/29672039